These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 34912244)

  • 1. Translational Control in Liver Disease.
    Balvey A; Fernandez M
    Front Physiol; 2021; 12():795298. PubMed ID: 34912244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential Functions of CPEB1 and CPEB4 Regulate Pathologic Expression of Vascular Endothelial Growth Factor and Angiogenesis in Chronic Liver Disease.
    Calderone V; Gallego J; Fernandez-Miranda G; Garcia-Pras E; Maillo C; Berzigotti A; Mejias M; Bava FA; Angulo-Urarte A; Graupera M; Navarro P; Bosch J; Fernandez M; Mendez R
    Gastroenterology; 2016 Apr; 150(4):982-97.e30. PubMed ID: 26627607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
    Tacke F; Weiskirchen R
    Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
    Ye Q; Zou B; Yeo YH; Li J; Huang DQ; Wu Y; Yang H; Liu C; Kam LY; Tan XXE; Chien N; Trinh S; Henry L; Stave CD; Hosaka T; Cheung RC; Nguyen MH
    Lancet Gastroenterol Hepatol; 2020 Aug; 5(8):739-752. PubMed ID: 32413340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies.
    Jarvis H; Craig D; Barker R; Spiers G; Stow D; Anstee QM; Hanratty B
    PLoS Med; 2020 Apr; 17(4):e1003100. PubMed ID: 32353039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A brief review on the rising incidence of chronic kidney diseases and non-alcoholic fatty liver disease.
    Nagy J; Kovács T
    Physiol Int; 2019 Dec; 106(4):305-310. PubMed ID: 31906711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic histopathology of morbid obesity: concurrence of other forms of chronic liver disease.
    Liew PL; Lee WJ; Lee YC; Wang HH; Wang W; Lin YC
    Obes Surg; 2006 Dec; 16(12):1584-93. PubMed ID: 17217634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-alcoholic fatty liver disease - A global public health perspective.
    Younossi ZM
    J Hepatol; 2019 Mar; 70(3):531-544. PubMed ID: 30414863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of fatty liver, dietary fatty acid supplements, and obesity in the progression of alcoholic liver disease: introduction and summary of the symposium.
    Purohit V; Russo D; Coates PM
    Alcohol; 2004 Aug; 34(1):3-8. PubMed ID: 15670659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatology through the crystal ball.
    Williams R
    Hepatol Int; 2019 Jul; 13(4):403-406. PubMed ID: 31273617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Treatment of Rapid Onset, Symptomatic de novo Non-alcoholic Steatohepatitis Following Liver Transplantation: A Case Report.
    Cuschieri JR; John BK; Miick R; Ortiz JA; Hashemi N
    J Clin Exp Hepatol; 2013 Mar; 3(1):70-4. PubMed ID: 25755474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD).
    Johnston MP; Patel J; Byrne CD
    Curr Pharm Des; 2020; 26(10):1079-1092. PubMed ID: 32003662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Defatting strategies in the current era of liver steatosis.
    Mazilescu LI; Selzner M; Selzner N
    JHEP Rep; 2021 Jun; 3(3):100265. PubMed ID: 34027337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PERFORMACE OF TRIGLYCERIDE-GLUCOSE INDEX ON DIAGNOSIS AND STAGING OF NAFLD IN OBESE PATIENTS.
    Smiderle CA; Coral GP; DE Carli LA; Mattos AA; Mattos AZ; Tovo CV
    Arq Gastroenterol; 2021; 58(2):139-144. PubMed ID: 34231659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions.
    Jonscher KR; Bruce KD
    Adv Exp Med Biol; 2019; 1134():33-58. PubMed ID: 30919331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global challenges in liver disease.
    Williams R
    Hepatology; 2006 Sep; 44(3):521-6. PubMed ID: 16941687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?
    Mikolasevic I; Orlic L; Franjic N; Hauser G; Stimac D; Milic S
    World J Gastroenterol; 2016 Aug; 22(32):7236-51. PubMed ID: 27621571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.